Yazar "Erden, Abdulsamet" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ N/A ]
    Öğe
    Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
    (Wiley, 2020) Atagunduz, Pamir; Kiraz, Sedat; Akar, Servet; Kucuksahin, Orhan; Erden, Abdulsamet; Coskun, Nihan; Yagiz, Burcu
    [Abstract Not Available]
  • [ N/A ]
    Öğe
    Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19: results from a multicenter Psoriatic Arthritis Registry (PsART-ID)
    (Springer London Ltd, 2023) Erden, Abdulsamet; Ayan, Gizem; Kilic, Levent; Solmaz, Dilek; Bakirci, Sibel; Kimyon, Gezmis; Gunal, Esen Kasapoglu
    BackgroundThis study aimed to assess the mortality of PsA before and during the COVID-19 pandemic.MethodsFrom the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry-March 2014-March 2020), and during the pandemic (March 2020-May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined.ResultsThere were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61-1.49), being higher in males [1.56 (0.92-2.63)] than females [0.62 (0.33-1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73).ConclusionThe mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies.
  • Küçük Resim
    Öğe
    SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA
    (Bmj Publishing Group, 2019) Kucuksahin, Orhan; Erden, Abdulsamet; Ilgen, Ufuk; Kiraz, Sedat; Ertenli, Ali Ihsan; Bilge, Nazife Sule Yasar; Kasifoglu, Timucin
    [Abstract Not Available]
  • [ N/A ]
    Öğe
    Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: Real life experience from the TReasure Registry
    (Clinical and Experimental Rheumatology S.A.S., 2024) Karadag, Omer; Farisogullari, Bayram; Yagiz, Burcu; Erden, Abdulsamet; Ademoglu, Zeliha; Kimyon, Gezmis; Sule Bilge, Nazife
    To evaluate the retention rate, treatment response and safety of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR). Methods The TReasure Registry is a multicentre, web-based registry of RA and spondyloarthritis patients across Turkey. DMARD-IR RA patients who received TCZ as first-line biologic treatment were included in this registry for efficacy and safety. Demographic and clinical data, treatments, and adverse events were collected. Drug retention rate was estimated using Kaplan-Meier analysis. Results Among 642 RA patients who ever used TCZ, 258 DMARD-IR RA patients (male/female: 18.2%/81.8%, mean age, 54.41 years) received TCZ as first-line biologic. The median disease duration was 97 (range, 60 179) months and the median TCZ treatment duration was 15 (range, 6 28) months. At the 6th and 12th months of TCZ treatment, the decrease in disease activity scores from baseline was significant. The Kaplan-Meier analysis revealed the retention rate of TCZ at the 12th, 24th, 36th, and 60th months as 81.1%, 73.8%, 66.2%, and 63.6%, respectively. Fifty-seven (22%) patients discontinued TCZ; the main reason being primary or secondary inefficacy (n=29). Conclusion Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies. Significant reductions not only in the disease activity score-28 but also in the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) scores, along with health assessment questionnaire (HAQ) scores, supported the impact of TCZ in RA management with a good safety profile. © 2024 Clinical and Experimental Rheumatology S.A.S.. All rights reserved.
  • [ N/A ]
    Öğe
    Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
    (Wiley, 2019) Ilgen, Ufuk; Turan, Sezin; Emmungil, Hakan; Sari, Alper; Erden, Abdulsamet; Kilic, Levent; Karadag, Omer
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?
    (Springer Heidelberg, 2022) Ilgen, Ufuk; Karadag, Omer; Emmungil, Hakan; Kucuksahin, Orhan; Koca, Suleyman Serdar; Erden, Abdulsamet; Bes, Cemal
    This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guerin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT-GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT-GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT-GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA.